Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients
- PMID: 35835583
- PMCID: PMC9841249
- DOI: 10.2967/jnumed.122.264112
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients
Abstract
18F-FDG PET/MRI might be the diagnostic method of choice for Hodgkin lymphoma patients, as it combines significant metabolic information from PET with excellent soft-tissue contrast from MRI and avoids radiation exposure from CT. However, a major issue is longer examination times than for PET/CT, especially for younger children needing anesthesia. Thus, a targeted selection of suitable whole-body MRI sequences is important to optimize the PET/MRI workflow. Methods: The initial PET/MRI scans of 84 EuroNet-PHL-C2 study patients from 13 international PET centers were evaluated. In each available MRI sequence, 5 PET-positive lymph nodes were assessed. If extranodal involvement occurred, 2 splenic lesions, 2 skeletal lesions, and 2 lung lesions were also assessed. A detection rate was calculated dividing the number of visible, anatomically assignable, and measurable lesions in the respective MRI sequence by the total number of lesions. Results: Relaxation time-weighted (T2w) transverse sequences with fat saturation (fs) yielded the best result, with detection rates of 95% for nodal lesions, 62% for splenic lesions, 94% for skeletal lesions, and 83% for lung lesions, followed by T2w transverse sequences without fs (86%, 49%, 16%, and 59%, respectively) and longitudinal relaxation time-weighted contrast-enhanced transverse sequences with fs (74%, 35%, 57%, and 55%, respectively). Conclusion: T2w transverse sequences with fs yielded the highest detection rates and are well suited for accurate whole-body PET/MRI in lymphoma patients. There is no evidence to recommend the use of contrast agents.
Keywords: Hodgkin lymphoma; MRI sequences; PET/MRI; whole-body imaging.
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Figures





Similar articles
-
Whole-Body Diffusion-Weighted MRI Compared to 18 FFDG PET/CT in Initial Staging and Therapy Response Assessment of Hodgkin Lymphoma in Pediatric Patients.Can Assoc Radiol J. 2020 May;71(2):217-225. doi: 10.1177/0846537119888380. Epub 2020 Jan 22. Can Assoc Radiol J. 2020. PMID: 32062992
-
Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?Pediatr Radiol. 2018 May;48(5):638-647. doi: 10.1007/s00247-018-4071-6. Epub 2018 Jan 23. Pediatr Radiol. 2018. PMID: 29362839
-
Comparison of diffusion-weighted MRI and [18F]FDG PET/MRI for treatment monitoring in pediatric Hodgkin and non-Hodgkin lymphoma.Eur Radiol. 2024 Jan;34(1):643-653. doi: 10.1007/s00330-023-10015-5. Epub 2023 Aug 5. Eur Radiol. 2024. PMID: 37542653 Free PMC article. Review.
-
Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.Radiol Med. 2023 May;128(5):556-564. doi: 10.1007/s11547-023-01622-9. Epub 2023 May 5. Radiol Med. 2023. PMID: 37145214 Free PMC article.
-
18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.Eur Radiol. 2020 Jul;30(7):3641-3649. doi: 10.1007/s00330-020-06703-1. Epub 2020 Mar 3. Eur Radiol. 2020. PMID: 32125513
Cited by
-
[18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference?Eur Radiol. 2023 Nov;33(11):8366-8375. doi: 10.1007/s00330-023-09840-5. Epub 2023 Jun 20. Eur Radiol. 2023. PMID: 37338559 Free PMC article.
-
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.Hemasphere. 2025 Jun 15;9(6):e70159. doi: 10.1002/hem3.70159. eCollection 2025 Jun. Hemasphere. 2025. PMID: 40519771 Free PMC article.
-
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.J Cancer Res Clin Oncol. 2023 Aug;149(9):6131-6138. doi: 10.1007/s00432-023-04587-4. Epub 2023 Jan 20. J Cancer Res Clin Oncol. 2023. PMID: 36662305 Free PMC article.
-
Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL.Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346. Blood Adv. 2024. PMID: 39058968 Free PMC article.
-
Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.Strahlenther Onkol. 2025 Aug 14. doi: 10.1007/s00066-025-02446-4. Online ahead of print. Strahlenther Onkol. 2025. PMID: 40810745
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous